These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3570479)

  • 21. Fusidic acid in other infections.
    Golledge C
    Int J Antimicrob Agents; 1999 Aug; 12 Suppl 2():S11-5. PubMed ID: 10528782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of efficacy of fusidic acid in the treatment of chlamydial conjunctivitis.
    Stenberg K; Mårdh PA
    Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):57-8. PubMed ID: 2303070
    [No Abstract]   [Full Text] [Related]  

  • 23. A study to compare the use of fusidic acid viscous eye drops and chloramphenicol eye ointment in an accident and emergency department.
    James MR; Brogan R; Carew-McColl M
    Arch Emerg Med; 1991 Jun; 8(2):125-9. PubMed ID: 1888407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: The treatment of acute infectious conjunctivitis with fusidic acid.
    Rietveld RP; ter Riet G
    Br J Gen Pract; 2006 Mar; 56(524):222. PubMed ID: 16536964
    [No Abstract]   [Full Text] [Related]  

  • 25. Fusidic acid viscous eyedrops--an evaluation of pharmacodynamics, pharmacokinetics and clinical use for UK optometrists.
    Doughty MJ; Dutton GN
    Ophthalmic Physiol Opt; 2006 Jul; 26(4):343-61. PubMed ID: 16792734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of effectiveness and tolerance of treatment with azithromycin 1.5% eye drops in bacterial conjunctivitis].
    Ambroziak AM; Szaflik JP; Hapunik A
    Klin Oczna; 2009; 111(1-3):46-9. PubMed ID: 19517846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
    Chang MH; Fung HB
    Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multicenter double-blind phase III study.
    Gallenga PE; Lobefalo L; Colangelo L; Della Loggia G; Orzalesi N; Velati P; Bujtar E; Ponte F; Damiani S; Bucci MG; Bonini S; Curatola MR; Palma LA; Bonomi L; Tomazzoli Gerosa L; Pagliarusco A; Milan E; Jauch A
    Ophthalmologica; 1999; 213(4):250-7. PubMed ID: 10420109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial.
    Rose PW; Harnden A; Brueggemann AB; Perera R; Sheikh A; Crook D; Mant D
    Lancet; 2005 Jul 2-8; 366(9479):37-43. PubMed ID: 15993231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
    Protzko E; Bowman L; Abelson M; Shapiro A;
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trimethoprim-polymyxin B sulphate ophthalmic ointment versus chloramphenicol ophthalmic ointment in the treatment of bacterial conjunctivitis--a review of four clinical studies. The Trimethoprim-Polymyxin B Sulphate Ophthalmic Ointment Study Group.
    J Antimicrob Chemother; 1989 Feb; 23(2):261-6. PubMed ID: 2540136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-bacterial acute conjunctivitis.
    Ali N
    Br J Gen Pract; 2006 Feb; 56(523):142. PubMed ID: 16464342
    [No Abstract]   [Full Text] [Related]  

  • 33. Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
    Haas W; Gearinger LS; Hesje CK; Sanfilippo CM; Morris TW
    Adv Ther; 2012 May; 29(5):442-55. PubMed ID: 22644963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fusidic acid-resistant Staphylococcus aureus (FRSA) carriage in patients with atopic eczema and pattern of prior topical fusidic acid use.
    Sule O; Brown NM; Willocks LJ; Day J; Shankar S; Palmer CR; Burrows NP
    Int J Antimicrob Agents; 2007 Jul; 30(1):78-82. PubMed ID: 17475448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
    Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
    Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistant Infantile Bacterial Conjunctivitis in Egypt: A Microbiology Study.
    Hashish AA; Elbakary MA; Allam WA
    J Pediatr Ophthalmol Strabismus; 2018 Mar; 55(2):135-139. PubMed ID: 29131910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Efficacy of 1% Chloramphenicol Eye Ointment Versus 2.5% Povidone-Iodine Ophthalmic Solution in Reducing Bacterial Colony in Newborn Conjunctivae.
    Bramantyo T; Roeslani RD; Andriansjah A; Sitorus RS
    Asia Pac J Ophthalmol (Phila); 2015; 4(3):180-3. PubMed ID: 26065506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical antibiotic prophylaxis for cataract surgery: a controlled trial of fusidic acid and chloramphenicol.
    Dallison IW; Simpson AJ; Keenan JI; Clemett RS; Allardyce RA
    Aust N Z J Ophthalmol; 1989 Aug; 17(3):289-93. PubMed ID: 2803775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice.
    Everitt HA; Little PS; Smith PW
    BMJ; 2006 Aug; 333(7563):321. PubMed ID: 16847013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
    Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.